Table 2.
Demographic, staging, disease, and treatment data for patients diagnosed with NSCLC in our single-institutional cohort.
| Demographic & Survival | Median age at diagnosis in years (range) | Gender |
Race |
Survival |
|||||
|---|---|---|---|---|---|---|---|---|---|
| Female | Male | White | Asian | Black | Other | Median follow up in days (IQR) | Median time to BrM in Days (IQR) | ||
| Total cohort (%) | 68 (38–94) | 845 (44.4) | 1059 (55.6) | 1766 (92.8) | 19 (1.0) | 77 (4.0) | 42 (2.2) | 550 (1325) | 26 (270) |
| Staging | T-stage at diagnosis |
N-stage at diagnosis |
M-stage at diagnosis |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | U | 0 | 1 | 2 | 3 | U | 0 | 1 | U | |
| Total cohort (%) | 794 (41.7) | 153 (8.0) | 335 (17.6) | 554 (29.1) | 68 (3.6) | 913 (48.0) | 157 (8.2) | 439 (23.1) | 270 (14.2) | 125 (6.6) | 1160 (60.9) | 668 (35.1) | 76 (4.0) |
| Disease characteristics | Histology |
Primary NSCLC Treatment |
Metastatic burden |
Brain metastases |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | Carcinoid | Carcinoma | Other | Surgery | Chemo | Radiation | 0 | 1 | 2 | 3+ | Y | N | |
| Total cohort (%) | 1007 (52.9) | 115 (6.0) | 681 (35.8) | 101 (5.3) | 572 (30.0) | 719 (37.8) | 884 (46.5) | 854 (44.9) | 694 (36.4) | 228 (12.0) | 128 (6.9) | 434 (22.8) | 1470 (77.2) |
U, unknown.